A MULTI-CENTER, SINGLE-ARM STUDY TO INVESTIGATE THE PHARMACOKINETICS AND SAFETY OF DUPILUMAB IN MALE AND FEMALE PARTICIPANTS ¿2 YEARS TO <12 YEARS OF AGE WITH UNCONTROLLED CHRONIC SPONTANEOUS URTICARIA (CSU) OR CHRONIC INDUCIBLE COLD URTICARIA (CICU)

Registry ID

PKM16982

Source registry

HEALTH_CANADA

Status

Closed

Study type

INTERVENTIONAL

Sponsor

SANOFI-AVENTIS CANADA INC

Start date

2023-03-24

Completion date

2025-12-12

Last update

2022-06-15

Conditions

• CHRONIC SPONTANEOUS URTICARIA (CSU)
• URTICARIA
• CHRONIC SPONTANEOUS URTICARIA

Related clinical trials

• A PHASE 3B LONG-TERM EFFICACY AND SAFETY EXTENSION STUDY OF BARZOLVOLIMAB IN PARTICIPANTS WITH CHRONIC SPONTANEOUS URTICARIA WHO HAVE COMPLETED CDX0159-12 OR CDX0159-13 (EMBARQ-CSULTE)
• A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BARZOLVOLIMAB IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA WHO REMAIN SYMPTOMATIC DESPITE H1 ANTIHISTAMINE TREATMENT (EMBARQ - CSU1)
• A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BARZOLVOLIMAB IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA WHO REMAIN SYMPTOMATIC DESPITE H1 ANTIHISTAMINE TREATMENT (EMBARQ - CSU2)
• AN OPEN-LABEL EXTENSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PK, IMMUNOGENICITY, AND CLINICAL RESPONSE OF MULTIPLE DOSES OF IV AK006 IN SUBJECTS WITH H1 ANTIHISTAMINE REFRACTORY CHRONIC SPONTANEOUS URTICARIA COMPLETING STUDY AK006-001
• A 52-WEEK MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, BASKET STUDY WITH AN OPEN-LABEL EXTENSION TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF REMIBRUTINIB (LOU064) IN CHRONIC INDUCIBLE URTICARIA (CINDU) IN ADULTS INADEQUATELY CONTROLLED BY H1-ANTIHISTAMINES
• A GLOBAL, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP, PHASE 3B STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF REMIBRUTINIB 25 MG B.I.D. IN COMPARISON TO PLACEBO WITH OMALIZUMAB 300 MG EVERY 4 WEEKS AS ACTIVE CONTROL OVER 52 WEEKS IN ADULT PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA INADEQUATELY CONTROLLED BY SECOND-GENERATION H1-ANTIHISTAMINES, AND AN OPEN-LABEL 52-WEEK OPTIONAL EXTENSION TO ASSESS LONG-TERM EFFICACY, SAFETY AND TOLERABILITY OF REMIBRUTINIB 25

View on source registry